The menopause transition and early postmenopausal period are associated with a 2-to 4-fold increased risk for clinically significant depressive symptoms. Although a few studies suggest that hormone therapy can effectively manage existing depression during this time, to our knowledge, there have been no studies testing whether hormone therapy can prevent the onset of perimenopausal and early postmenopausal depressive symptoms.
D epression risk is known to increase among women in the menopause transition and early postmenopausal period, with rates of major depressive disorder 1 and clinical elevations in depressive symptoms [2] [3] [4] roughly doubling to tripling compared with premenopausal and late postmenopausal rates. Increased sensitivity to the extreme estradiol fluctuation that characterizes the menopause transition has been implicated. 3, 5, 6 Although a few trials suggest that estrogen therapy, with 7,8 or without 9, 10 progesterone, which might act to minimize estradiol fluctuation and/or withdrawal, is an effective treatment for perimenopausal depression, to our knowledge, this is the first study to examine the efficacy of hormone therapy, in this case, transdermal estradiol plus intermittent micronized progesterone (TE+IMP), in preventing the development of depressive symptoms in initially euthymic perimenopausal and early postmenopausal women. This study further sought to identify baseline characteristics predicting TE+IMP's effect on mood. Several factors known to be associated with an increased vulnerability to perimenopausal depression and/or other reproductive mood disorders, including recent life stress, 1,2 a positive history of depression, 1,3,11 a history of physical or sexual abuse, 12,13 and more severe vasomotor symptoms, 3, 4, 14 were therefore considered as potential moderators of TE+IMP's effects. Indicators of the preintervention hormonal environment, including menopausal stage, were also considered.
Methods

Participants
Between October 2010 and January 2015, 172 women aged 45 to 60 years, medically healthy and perimenopausal or early postmenopausal according to the Stages of Reproductive Aging Workshop criteria, 15 were self-referred in response to advertisements posted throughout the community and on social media. The final participant completed the trial in February 2016. Data were collected at the University of North Carolina at Chapel Hill. Women were euthymic on study enrollment according to the Structured Clinical Interview for DSM-IV. The trial protocol was approved by the University of North Carolina's institutional review board. All participants provided informed, written consent prior to participating and received up to $1425 in compensation for participating in full compliance.
Trial Design
The Perimenopausal Estrogen Replacement Therapy study was designed to examine the mood and cardiovascular benefits of TE+IMP among perimenopausal and early postmenopausal women and to investigate several mechanisms underlying estradiol's effects. In this article, only TE+IMP's effects on the study's primary mood outcome, depressive symptoms, are reported. The Perimenopausal Estrogen Replacement Therapy study used a randomized, double-blind, placebo-controlled design in which 172 women were enrolled and randomly assigned to treatment with either patches of 0.1 mg of 17β-estradiol or placebo patches (developed by 3M pharmaceuticals) for 12 months. Oral micronized progesterone (200 mg/d for 12 days) was also given every 2 to 3 months to women receiving active TE+IMP to protect the endometrium, and an identical schedule of placebo pills was implemented for women receiving the placebo. Postrandomization study visits occurred at months 1, 2, 4, 6, 8, 10, and 12. To allow for the examination of the effects of estradiol without the confound of progesterone, no visits occurred while women were taking progesterone. The trial protocols can be found in Supplement 1 and additional details regarding the trial design can be found in the eMethods of Supplement 2.
Measures
Depressive symptoms were assessed at each study visit using the Center for Epidemiologic Studies-Depression Scale (CES-D). 16 Vasomotor symptom bother was measured at each visit using the Vasomotor Subscale of the Greene Climacteric Scale. 17 Baseline estradiol levels were measured, in serum, at the study enrollment session. The assay procedure is described elsewhere. 5 For women with an intact uterus, reproductive stage, assessed at enrollment, was defined as follows: early perimenopause, defined as menstrual cycle length at least 7 days longer than usual; late perimenopause, defined as at least 2 skipped cycles and an interval of amenorrhea of at least 60 days but within 1 year of the last menstrual period; and early postmenopause, defined as an interval of amenorrhea between 1 and 2 years. This classification scheme is very similar to the Stages of Reproductive Aging Workshop criteria. 15 A history of a major depressive episode was identified using the Structured Clinical Interview for DSM-IV at the study enrollment session. Stressful life events during the 6 months before the baseline assessment were measured using the Life Events Survey 18,19 interview, modified to include only those events that are considered moderate to severely stressful based on previous studies with interviewer-based objectively rated stresses. [20] [21] [22] Experiences of sexual and physical
Statistical Analysis
Effect of Treatment Unless otherwise specified, an intent-to-treat analysis was performed. First, we tested the main effect of treatment (placebo vs TE+IMP) on the risk of developing clinically significant depressive symptoms (CES-D score ≥16), the primary outcome. A score of 16 or greater on the CES-D is commonly used as a cutoff for identifying potential clinical depression 26 and is associated with major depression. 27 Second, we tested the moderating effect of several baseline characteristics on the effect of treatment: reproductive stage at enrollment, baseline estradiol levels, baseline vasomotor symptom bother, history of a major depressive episode, stressful life events, and history of physical or sexual abuse. Estradiol levels, vasomotor symptom bother, and stressful life events were treated as continuous variables; baseline estradiol level was standardized to have a mean of 0 and a standard deviation of 1. All analyses were conducted using SAS, version 9.2 (SAS Institute Inc). Logistic regression was used to examine the effect of treatment (and potential moderation by baseline characteristics) on the risk of developing a CES-D score of at least 16. Poisson regression using PROC GENMOD examined the effect of treatment and potential moderation of treatment on the number of visits during which a CES-D score of at least 16 was obtained (0 to 7). To test for potential moderating effects, the variable of interest and a treatment-by-variable of interest interaction term were added as predictors in the analyses described here. To ensure that any mood benefits observed were not owing to a reduction in vasomotor symptoms, mean change in vasomotor symptom bother averaged across the entire study was included as a covariate, as was prerandomization enrollment CES-D score.
Secondary analyses examined the effect of treatment (placebo vs TE+IMP) on continuous CES-D scores, a repeatedmeasures regression analysis using PROC MIXED (for mixed models) with 8 repeated measures (prerandomization [denoted visit −1] and months 1, 2, 4, 6, 8, 10, and 12). Change in vasomotor symptom bother relative to enrollment levels and prerandomization enrollment CES-D score were included as covariates. A first-order autoregressive covariance structure was specified for within-person error. The Kenward-Roger method was used for computing degrees of freedom for tests of fixed effects. For significant interaction effects, simple effects of treatment condition on the least squares means of the outcome variable at key levels of the moderating variable were examined. Sensitivity analyses were used to identify extreme outliers, defined as values 3 or more interquartile ranges lower than the first quartile or greater than the third quartile (SAS Institute Inc, 2011). The effect of treatment on CES-D score was reexamined with these outliers removed. Because PROC MIXED does not delete missing data listwise, all available data were used. A 2-sided value of P less than .05 was considered statistically significant.
Results
Participant Characteristics
One hundred seventy-two women entered the trial ( Figure 1 ). As seen in Table 1 , women randomized to TE+IMP and placebo did not significantly differ in terms of any baseline demographic or psychosocial variables. By visit 12, 17% of women assigned to placebo were early perimenopausal (n = 12 of 69), 49% were late perimenopausal (n = 34), and 32% were early postmenopausal (n = 22). Twenty-five percent of participants (n = 43 of 172) obtained a score of at least 16 at least once during the course of the study. The mean (SD) CES-D score among visits in which a score of at least 16 was obtained was 22.0 (6.5). Additional details regarding baseline participant characteristics and adherence can be found in the eResults of Supplement 2.
Main Effect of Treatment
Women assigned to placebo were more likely than those assigned to TE+IMP to score at least 16 on the CES-D at least once during the intervention phase (OR , 2.5; 95% CI, 1.1-5.7; P = .03; Figure 2 ) and scored at least 16 on the CES-D during more visits compared with those assigned to TE+IMP (β, .7; SEM, 0.2; P = .002).Women receiving placebo also exhibited a significantly higher mean CES-D score across the 12-month intervention compared with those assigned to TE+IMP ( Table 2) . Mean (SD) unadjusted CES-D scores of the placebo and TE+IMP groups were 5.6 (5.7) and 4.2 (5.3) at visit 6, respectively, and 5.7 (7.6) and 4.0 (5.0) at visit 12. The effect of treatment on CES-D scores remained significant when 6 outliers were removed from the analysis (β, 1.1; SEM, 0.5; P = .03). Additional sensitivity analyses confirmed that these results also remained significant when adjusting for participants' beliefs about their treatment assignment.
Moderators of the Effect of Treatment
Reproductive Stage A significant interaction between treatment and reproductive stage at study enrollment was found for mean CES-D scores (β, −1.97; SEM, 0.80, P = .03) such that mood benefits of TE+IMP vs placebo were evident among women in the early (β, −4.2; SEM, 1.2; P < .001) but not the late (β, −0.9; SEM, 0.3; P = .23) menopause transition or among postmenopausal women (β, −0.3; SEM, 1.1; P = .92) ( Table 2 ; eFigure in Supplement 2). A similar interaction was seen between treatment and reproductive stage in predicting the number of visits during which a CES-D score of at least 16 was obtained (χ 2 =6.9;P = .03): TE+IMP was associated with women. The interaction between treatment and reproductive stage did not reach significance in predicting the likelihood of experiencing clinically significant depressive symptoms (CES-D ≥16) (χ 2 =4.1;P = .13).
Stressful Life Events
A significant interaction between treatment and number of stressful life events in the 6 months preceding study enrollment on mean CES-D score was observed (Table 2) such that a beneficial effect of treatment was more apparent in those with a greater number of stressful life events. Figure 3 depicts the effect of treatment on CES-D scores throughout the study among women reporting 0, 1, or 2 or more stressful life events at baseline. Although stressful life events did not moderate the effect of treatment on the likelihood of obtaining a CES-D score of at least 16 (β, 0.04; SEM, 0.17; P = .79), there was a marginally significant interaction between treatment and number of stressful life events on the total number of instances of clinically significant elevations in depressive symptoms experienced over the intervention period (β, 0.3; SEM, 0.2; P = .06) such that TE+IMP was associated with 1 less instance of a CES-D score of at least 16 among women with 2 or more recent events compared with placebo (β [SE], 1.0 [0.4];P = .007) but not among women with 0 (β, −0.2; SEM, 0.4, P = .67) or 1 (β, 0.5; SEM, 0.5, P = .33) stressful life event.
Nonsignificant Moderators
Baseline estradiol levels, baseline vasomotor symptom bother, depression history, and abuse history were not found to be significant moderators of TE+IMP's effects on depressive symptoms, the likelihood of obtaining a CES-D score of at least 16, or on the number of times a CES-D score of at least 16 occurred.
Adverse Effects
As would be expected given the purpose of the progesterone regimen was to induce vaginal bleeding, adverse effects were reported more commonly by participants assigned to TE+IMP than those assigned to placebo, as determined by χ 2 analyses including spotting (64% vs 34%; P < .01), mild or moderate bleeding (80% vs 44%; P < .01), heavy bleeding (37% vs. 13%; P < .01), and prolonged bleeding (15% vs 1%; P < .01). The treatment groups did not differ in their reporting of breast tenderness, bloating, headache, migraine headaches, leg pain, fatigue, gastrointestinal symptoms, shortness of breath, skin irritation, hypertension, weight gain, breast lumps, or vision changes. There were 3 severe adverse events requiring study termination and medical treatment: 2 cases of major depressive disorder in the placebo group and 1 case of an acute deep vein thrombosis in the TE+IMT group.
Discussion
To our knowledge, this study is the first to longitudinally examine the prophylactic mood benefits of TE+IMP in initially euthymic women during the menopause transition and early postmenopausal period. During the 12-month intervention, rates of clinically significant depressive symptoms (CES-D score ≥16) were found to be 17% in the TE+IMP group and 32% in the placebo group, suggesting that TE+IMP effectively prevents the development of clinically significant depressive symptoms in this population. Importantly, these results were significant despite statistically adjusting for change in vasomotor symptom bother, suggesting that 
TE+IMP Placebo
A significant effect of treatment is evident among the high-stress (n = 55; P = .005) but not low-stress (n = 72; P = .53) or moderate-stress (n = 46, P = .70) women. CES-D indicates Center for Epidemiological StudiesDepression Scale; TE+IMP, transdermal estradiol plus intermittent micronized progesterone.
Research Original Investigation
Transdermal Estradiol and Micronized Progesterone for the Prevention of Depression in the Menopause Transition TE+IMP has direct prophylactic mood benefits that are independent from its beneficial effects on menopausal symptoms, as previously observed in women with major depressive disorder treated with TE+IMP. 6 It is noteworthy that more women receiving TE+IMP compared with those taking placebo experienced heavy (37% vs 13%) or prolonged (15% vs 1%) vaginal bleeding, which may be an important factor when considering TE+IMP as a treatment option. Nonetheless, despite early concerns that hormone therapy increases the risk of breast cancer and cardiovascular events, sparked by the initial findings of the Women's Health Initiative, 28 research has since demonstrated that hormone therapy, particularly TE+IMP, is safe for perimenopausal and early postmenopausal women when given at the lowest dose for the shortest amount of time to treat menopausal symptoms. 29, 30 The North American
Menopause Society, the American Society for Reproductive Medicine, and the Endocrine Society agree that hormone therapy is indicated for the treatment of menopausal symptoms in younger women who are within 10 years of menopause. 31 If confirmed in a larger sample of early perimenopausal women, the findings of this study, in combination with the few small trials finding estradiol therapy to be an effective treatment for perimenopausal depression, [7] [8] [9] [10] suggest that hormone therapy may also be indicated for the prevention and/or treatment of depressive symptoms appearing in the early menopause transition, regardless of whether menopausal symptoms are present.
To our knowledge, this study is also the first to assess baseline predictors of TE+IMP's prophylactic mood benefits. The findings suggest that TE+IMP may be particularly beneficial for women in the early menopause transition and in women reporting more baseline stressful life events. Baseline vasomotor symptoms, a positive history of major depression, and a history of physical or sexual abuse were not associated with a beneficial effect of TE+IMP, suggesting that women may benefit from TE+IMP regardless of these baseline characteristics. Given that a history of depression is a strong risk factor for the development of perimenopausal depressive symptoms, 1,3,11 it is somewhat surprising that it was not found to moderate the effects of TE+IMP. However, this is consistent with the findings of a small pilot study 10 observing that neither vasomotor symptoms nor depression history moderated the beneficial effects of TE on perimenopausal depression. 10 While the reasons that depression history did not predict a beneficial effect of TE+IMP are unknown, this negative finding is likely, in part, owing to TE+IMP's efficacy in those without a history of depression. The fact that depression history was associated with greater mean levels of depressive symptoms across both treatment groups also suggests that women with a history of depression are susceptible to perimenopausal depressive symptoms through mechanisms, whether neurobiological or psychosocial, that are unaffected by TE+IMP. These findings have important clinical implications. First, our findings confirm previous studies suggesting that the incidence of clinically significant depressive symptoms is not uncommon in perimenopausal and early postmenopausal women, particularly in the early perimenopausal period and among women experiencing stressful life events. Second, our findings suggest that a brief clinical interview assessing menstrual bleeding patterns and the presence of stressful life events may be best suited to identifying the patients for whom TE+IMP will be most beneficial during the menopause transition. In this way, these findings, if replicated, have relevance for the individualization of the therapeutic approach for women at this reproductive stage.
Our novel findings that reproductive stage and recent stressful life events predict the prophylactic mood benefit of TE+IMP begs the question as to why that might be the case. Owing to multiple simultaneous changes in the reproductive axis, triggered by advancing age, the menopause transition is characterized by increased estradiol fluctuation owing to higher estradiol peaks and lower estradiol troughs than the mean menstrual cycle [32] [33] [34] [35] ; in contrast, the late postmenopausal period, when depression risk declines, is characterized by low but stable estradiol levels. Prior work has observed that women with a history of perimenopausal depression exhibit a rapid increase in depressive symptoms following an abrupt experimental withdrawal from estradiol that is not observed in women without such a history, 6 supporting the notion that the changing hormonal milieu of the menopause transition contributes to the increased risk for perimenopausal depression. By raising trough estradiol levels, TE+IMP may minimize the magnitude of estradiol withdrawal experienced in the menopause transition. Based on 1 report, 36 TE may also minimize instances of extreme estradiol fluctuation by reducing the incidence of ovulation in perimenopausal women; however, it likely does not uniformly do so. The observation that number of stressful life events moderates the effect of treatment is consistent with our 2015 report suggesting that perimenopausal women experiencing greater estradiol variability are more emotionally sensitive to psychosocial stress in the laboratory and also more prone to depressive symptoms in the context of stressful life events. 5 A 2015 conceptual review 33 posited a neurobiological mechanism by which perimenopausal estradiol variability may trigger increased sensitivity to stress involving GABAergic influences on the hypothalamicpituitary-adrenal axis, 33 resulting in an increased susceptibility to depressed mood in the context of psychosocial stressors. A reduction in estradiol variability (via increasing trough levels or preventing ovulation) may be a mechanism contributing to TE+IMP's prophylactic mood benefits among women with a greater number of stressful life events, although this study was not designed to examine TE+IMP's effects on estradiol variability.
Limitations and Strengths
This study has several limitations. First, more frequent assessments of estradiol levels before and during treatment would have allowed us to more directly test the hypothesis that reducing the magnitude of fluctuation in estradiol levels represents a mechanism by which TE+IMP benefits mood. Relatedly, prerandomization estradiol measurements would have been best taken at standard times in relation to women's men- strual cycles (for women who were still menstruating) such as during the early follicular phase. Second, the active and placebo patches were not identical. However, our findings remain significant when adjusting for participants' beliefs about their treatment condition. This study also had many notable strengths. First, to our knowledge, it is the first to assess whether TE+IMP can prevent the emergence of clinically significant depressive symptoms in initially euthymic perimenopausal and early postmenopausal women. Second, its comprehensive assessment of multiple psychosocial variables allowed for a unique investigation of predictors of treatment response. Third, its 12-month duration and bimonthly assessment of symptoms allowed us to examine the progression of symptoms over time.
Conclusions
The findings of this study confirm that perimenopausal and early postmenopausal women are at high risk for developing clinically significant depressive symptoms. To our knowledge, we are the first to report that TE+IMP administration prevents this transition-related increase in risk for depressive mood. Health care professionals should be alert to the high risk for clinically significant depressive symptoms in this population. If our results are confirmed in a larger sample, clinicians may consider using TE+IMP as a prophylactic treatment in the prevention of clinically significant depressive symptoms in medically eligible perimenopausal and early postmenopausal women.
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Purpose and Rationale
102
The following are the driving assumptions of this study: beneficial effects of ERT on cardiovascular and mood regulation can be predicted.
180
Consequently, the aim of the proposed research is to first identify a profile (physiologic and diagnostic mammogram will be allowed to continue in the study.
347
In order to control as much as possible for extraneous factors that vary with depression and 348 impact cardiovascular risk (e.g., diet and exercise) all subject will have the American Heart 349 Association DASH diet as well as exercise guidelines reviewed with them and each will be 350 encouraged to adhere to them throughout the study (enclosed for review). We will review these
351
with the subject at every study visit. This strategy will also minimize the likelihood that subjects withdrawal.
354
II. BASELINE PRE-TREATMENT ASSESSMENTS (TIME 1)
355
Subjects will arrive at the laboratory following an overnight fast have fasting blood samples 356 taken for glucose and insulin. A meal will then be provided and subjects will undergo the 357 following laboratory testing procedures. which stroke volume will be determined and HR will be determined by the interbeat interval.
523
Cardiac output and total peripheral resistance are calculated using standard formulae. To control 524 for differences in BMI, measures will be adjusted for body surface area, yielding indexed scores 
563
The measure of lifetime sexual and physical abuse history is based on previous studies by criteria are intended to benefit to some degree since they will receive valuable feedback on their 576 current medical and psychiatric status and referral for treatment when indicated. Society may 577 benefit if this study yields knowledge on predictors of ERT benefit in perimenopausal women.
578
Risks and Measures to Minimize Risks
579
The most likely risks involve side effects associated with the use of reproductive hormones
580
(estradiol or progesterone).
581
The most frequent side effects associated with estradiol use include edema, breast tenderness, More Rare yet Serious Risks:
591
The risk of venous thromboembolism (VTE) is clearly increased with HRT, with the risk 592 influenced by age and preparation/type therapy. In the Women's Health Initiative Trial, the risk
593
of VTE was greater with combined estrogen + progestin (HRT) (HR 2.06) than with conguated receive the randomization code by subject ID from Investigational Drug Services. In the event that it is medically necessary to become unblinded to treatment assignment, he will be able to do 755 so very quickly.
756
We also have a plan for the monitoring of medical conditions that may emerge during the course for a finer assessment of precisely when women come in for a "visit," as visits rarely take place 786 on exactly the day planned, and (2) the covariance structure is necessarily simpler, leading to 787 more efficient mixed models. For comparisons assessing change over time, we will assess this 788 change as a difference between treatments or groups, as stated with respect to specific 789 hypotheses, on differences between baseline and month 12 least squares means (LSMs). The 790 month 6 CV data will be part of the mixed model predicting the 12 month least squares means.
791
That is, the mixed model is an Intent-to-Treat analysis which uses all available data to make a form the difference between resting and stress measures, yielding reactivity for each measure.
814
We will calculate mean and SD for each measure at baseline (pre-treatment) and use those to 815 standardize each measure at baseline (pre-treatment) and during the intervention to a common 816 scale. We will then add the z-scores for the 4 measures together to form our stress reactivity 817 composite at each point measured. women. If confirmed, the following parallel hypotheses will be examined in hierarchical order:
844
In women with a history of DEP: 1) there will be a greater increase in rate of metabolic risk; and 845 2) a greater reduction in endothelial flow-mediated dilatation and baroreceptor sensitivity. 
853
In the 320 women randomized to treatment we will test the following hypotheses: . These hypotheses will be tested as interactive effects (history by treatment).
867
H2:
Although no subjects will be depressed at baseline, active treatment will be associated with Affective Instability (tested with sensitivity analyses). 
POWER AND SAMPLE SIZE CALCULATIONS FOR EACH SPECIFIC AIM:
It is not feasible to conduct power analyses for every hypothesis. While this is a mechanistic study designed, in part, to examine mediators of E2's beneficial effects on CV risk and DEP, we 919 must first be able to detect a beneficial effect of E2. Thus, we conduct power for Aim 3, H2.
920
We also felt it important, however, to confirm we are powered to detect meaningful differences 
Participants
Women without a uterus but with at least one ovary retained were included in the study if: 1) they were experiencing vasomotor symptoms and their baseline estradiol levels were above postmenopausal concentrations (> 40 pg/ml) (n =15) or, 2) they were not experiencing vasomotor symptoms but had baseline estradiol > 40 pg/ml and baseline FSH levels > 14 pg/ml (n=2), which is two standard deviations above the mean level of a previously-recruited sample of reproductive-aged women, in line with STRAW staging guidelines 1 . However, these women did not take intermittent micronized progesterone and were not included in the reproductive stage moderation analyses. Women with both ovaries removed were included if the bilateral oophorectomy occurred in the past 24 months and they had been menstruating regularly prior to the procedure (n = 1). These women were not included in reproductive stage moderation analyses.
Exclusion criteria included current major depressive disorder or a trauma-or stressrelated disorder with severity greater than mild, a history of severe substance use within the past 10 years, a history of suicide attempts, bipolar or other psychotic disorders, current use of psychotropic medication, hormonal preparations, or herbal compounds indicated for menopausal symptoms (e.g. Black Cohosh) or mood (e.g. St. John's Wort), use of statins or antihypertensive agents other than diuretics, blood pressure >140/90 mmHg, fasting LDL  190 mg/dl (women with borderline elevated LDL cholesterol (190-200 mg/dl) at baseline were allowed into the trial if their physician was not intending to treat them over the course of the subsequent 12 months) or fasting glucose  7.0 mmol/l (126 mg/dl), use of anti-inflammatory agents (>10 times/month) unless they were on a stable regimen, endometrial hyperplasia, abnormal uterine anatomy, history of thrombophlebitis or thromboembolic disorders, history of estrogen-dependent neoplasias, gall bladder disease, liver dysfunction or other disorders for which estrogen or progesterone use is contraindicated, any history of any cardiovascular disease, arteriosclerosis, heart attack or stroke, atrial fibrillation, frequent premature atrial or ventricular beats, or other rhythm abnormalities, diabetes (Type I or II), body mass index > 35, smoking >10 cigarettes per day, any history of migraine in current cigarette smokers, known sensitivities to any ingredient in the transdermal estradiol system. To be eligible for the study, women also must have had a normal mammogram within one year of study enrollment. All women underwent a pelvic exam with a study physician to screen for any signs or history of endometrial disorder or abnormal uterine or ovarian anatomy. An endometrial biopsy was performed to rule out endometrial cancer in cases of concerning bleeding patterns. To control as much as possible for extraneous factors that vary with depression and impact cardiovascular risk (e.g. diet and exercise), all participants were given information on the American Heart Association DASH diet and exercise guidelines and were encouraged to adhere to them throughout the study.
The following exclusion criteria were applied to minimize the risk of breast or ovarian cancer: a personal history of breast cancer; a personal history of even one breast biopsy with atypical hyperplasia, though women with a history of > 1 breast biopsy were allowed to enter the trial if there was no personal or family history of breast cancer in first or second degree relatives and if the documented biopsy results are consistent with minimal proliferative disease, as described by Vogel et al., 2008 2 ; more than one first degree relative with breast cancer; premenopausal breast cancer in even one first degree relative; more than three first, second, or third-degree relatives with breast cancer regardless of age; two or more first-degree relatives with any cancer with onset before age 60 (except tobacco-related lung cancer since it is associated with a low-penetrance gene); multiple primary cancers in a single relative (except tobacco-related lung cancer since it is associated with a low-penetrance gene); any male breast cancer (as it is almost exclusively related to the BRCA 1/2 mutation); ovarian cancer in even one first-degree relative since that is associated with a 25% chance of having the BRCA 1 mutation (Schwartz et al., 2008) ; any known BRCA mutation in first, second or third-degree relatives, unless the woman had tested negative for the BRCA mutation; a personal history of irradiation to the breast or chest wall prior to the age of 30, such as for Hodgkin disease; Ashkenazi Jewish descent (those tracing their roots to central and eastern Europe) since two BRCA1 and one BRCA2 mutations are observed with higher frequency in Ashkenazi Jews, unless there was no family history of cancer.
Modifications to eligibility criteria initiated following trial commencement: Due to challenges with participant recruitment, several changes were made to the originally-proposed eligibility criteria to facilitate recruitment, resulting in the above-described criteria. These included the following changes: early postmenopausal (in STRAW +1b) were initially excluded but later allowed to enter the trial; the acceptable age range was extended from 45-55 to 45-60; an initial requirement that all women have an FSH level >2 SD above mean premenopausal levels was removed; women without a uterus or having undergone an endometrial ablation were initially excluded but later allowed to participate if they met the above-mentioned requirements related to estradiol and/or FSH levels; having had a bilateral oophorectomy was initially exclusionary but was later allowed if it had occurred within 24 months and the participant had been menstruating regularly prior to the procedure; an initial requirement of having a baseline CES-D score ≤8 in the women without a history of depression was removed; women with borderline elevated LDL cholesterol (190-200 mg/dl) were initially ineligible. More details about amendments made to participant eligibility criteria can be found in the Trial Protocol.
Details about the Intervention
The placebo patches generated by 3M Pharmaceuticals were not identical to the Climara® TE+IMP system in that the active Climara® patches was labeled with the brand and dosage of the patch, which was missing from the placebo patch. In an effort to maintain the double-blind despite this difference in appearance, 2/3 of active patches were the generic version of Climara® and study personnel were instructed that multiple forms of both the placebo and active patches existed. All placebo patches were 3M placebo patches. The patch that any particular woman received remained identical throughout her involvement. Women randomized to receive active TE+IMP wore a patch to deliver 0.025 mg of estradiol over a 24-hour period for the first two weeks, 0.05 mg for the next four weeks and 0.10 mg of estradiol for the remainder of the study. Though 0.10 mg was the target dose, five women were maintained on 0.05 mg and three were maintained at 0.025 mg to mitigate side effects. To monitor compliance, participants' used patches were collected and counted at each study visit. Plasma estradiol levels were also measured at months 6 and 12.
The study statistician created the randomization scheme using a 1:1 ratio of permuted blocks of size 4 by two levels of depression history, with the maximum imbalance of size 2 and 20. Mate or close relative was arrested for a serious crime or went to jail 21. You were robbed or your home was burglarized 22. Your partner became pregnant, had or adopted a baby 23. Ending of your formal schooling 24. You left home for the first time 25. Son or daughter moved away from home for the first time 26. Moved residence more than once in the past 6 months eResults Baseline Stressful Life Events 60% of our sample reported at least one stressful life event within six months of study entry. The most common stressful life events reported included: death or serious illness of a close family member or close friend (30%), major financial difficulties (16%), working at least 60 hours/week for at least 1 month (12%), job loss or unemployment (12%), estrangement or serious arguments with a family member (9%), son or daughter moving away from home for the first time (6%), divorce or separation (5%) and major illness (4%).
Treatment Adherence
Information regarding visit attendance can be found in Figure 1 . Treatment adherence was good, with only 12 (7%) of participants being flagged as potentially poor compliers by the research staff based on the number and appearance of the used returned patches. With regards to treatment blinding, 63% and 39% of participants in the TE+IMP and placebo conditions were accurate at every study visit in guessing their treatment assignment, respectively. The remaining participants were either consistently inaccurate (12 vs. 35%), were unsure (3 vs. 6%) or were inconsistent in their beliefs (22% vs. 20%). The accuracy rates of the two treatment groups (63 vs. 39%) were found to be both significantly different from each other (p < .01) and significantly different than chance levels in chi-square analyses (ps < .05). For this reason, we performed additional sensitivity analyses to ensure that participant unblinding did not account for our results.
Effect of Treatment on Estradiol Levels
Paired t-tests comparing estradiol levels pre-and post-randomization (averaged across visits 6 and 12) revealed that the TE+IMP group (t(60) = 4.9, p<.0001) but not the placebo group (t(75) = -1.1, p = .27) experienced a significant increase in estradiol levels such that the TE+IMP group had significantly higher estradiol levels in the treatment phase compared to the placebo group (M (SD) = 148.6 (77.0) versus 100.0 (57.3) pg/ml; p<.0001). Women assigned to TE+IMP experienced a significantly greater decrease in vasomotor symptom bother over the course of the study compared to women assigned to placebo (M (SD) = -1.7(1.8) vs. -0.8(1.5), p < .01).
Effect of Baseline Characteristics on Depressive Symptoms across Both Treatment Groups
Although Table 2 indicates that none of the treatment moderators were predictive of depressive symptoms in statistical models that included treatment assignment and a treatmentby-moderator interaction term, several of the moderators were significant predictors of mean CES-D score when only the moderator variable and baseline CES-D score were included as independent variables. Baseline stressful life events ( (SE) = 1.0(0.2), p < .0001), a history of depression ( (SE) = 1.54(0.5), p < .01) and baseline vasomotor symptom bother ( (SE) = 0.34(0.1), p = .02) predicted a higher mean CES-D score. Reproductive history was also a significant predictor of mean CES-D score (p = .01) such that women in the early postmenopausal period (M(SE) = 3.9(0.6)) had significantly lower scores compared to early perimenopausal (M(SE) = 6.1(0.6); p <.01) or late perimenopausal (M(SE) = 5.5(0.4), p = .01) women. Neither baseline estradiol (p = .81) nor abuse history (p = .13) significantly predicted depressive symptoms.
